HIGHFDA DEVICE

Ion Beam Applications PROTEUS 235 Recalled for 4 Units Worldwide (2026)

Ion Beam Applications S.A. recalled four PROTEUS 235 proton therapy systems distributed worldwide, including Florida in the United States, and the countries of Italy and Japan. The defect disables the Therapy Safety System's Universal Beam Triggering Interface, so the system may not stop beam delivery if the Healthy Signal from an external gating device is lost. Patients and healthcare providers应该

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DEVICE
Recall date
February 3, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
February 3, 2026
Hazard Level
HIGH
Brand
Ion Beam Applications
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Medical Devices; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Ion Beam Applications
Product type
Proton Therapy System
Model numbers
PROTEUS 235, 05404013801138, SBF103 (JP), SBF124 (EU), SBF133 (US), SBF140 (EU)
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    February 3, 2026

  2. Reported by FDA DEVICE

    March 18, 2026

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

It was identified that eh Universal Beam Triggering Interface (UBTI) is disabled in the Therapy Safety System (TSS) configuration. In this condition, the TSS does not interrupt the beam delivery if the Healthy Signal from an external gating device is lost. This may lead to a risk of mistreatment when external gating devices are used.

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Ion Beam Applications S.A. or your healthcare provider for instructions. Notification method: Letter

About This Product

PROTEUS 235 is a proton therapy system used in cancer treatment. Hospitals and clinics purchase it for precise radiation therapy.

Why This Is Dangerous

If the therapy safety mechanism does not interrupt beam delivery when gating signals are lost, patients may receive mistreatment.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Recalled devices require clinicians to halt treatments until guidance is provided.

Practical Guidance

How to identify if yours is affected

  1. Confirm device is PROTEUS 235 with the listed serial numbers
  2. Review recall letter for instructions

Where to find product info

Recall letter and FDA enforcement page; manufacturer communications

What timeline to expect

No specific timeline published; follow manufacturer guidance

If the manufacturer is unresponsive

  • Escalate with hospital risk management
  • File a formal complaint with the FDA if device remains in service without action

How to prevent similar issues

  • Verify safety features during system configuration
  • Confirm gating interfaces are correctly implemented before use in clinical settings.

Documentation advice

Document all communications with the manufacturer, hospital administrators, and patients.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: PROTEUS 235 proton therapy system. Brand: Ion Beam Applications. Model numbers: PROTEUS 235; UDI-DI 05404013801138. Serial Numbers: SBF103 (JP), SBF124 (EU), SBF133 (US), SBF140 (EU). Sold worldwide. US distribution in Florida, plus Italy and Japan. Recall date: 2026-02-03. Status: ACTIVE. Price: Unknown.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 4 units recalled worldwide (1 US, 3 outside US)
  • Product: PROTEUS 235; UDI-DI 05404013801138; Serial Numbers: SBF103 (JP), SBF124 (EU), SBF133 (US),S
  • Recall Date: 2026-02-03; Status: ACTIVE; Hazard Level: HIGH
  • Remedy: Stop using immediately; follow manufacturer instructions; notification by letter
  • Replacement products: Varian ProBeam proton therapy system, Mevion S250 proton therapy system, and I
  • No injuries or incidents reported

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
ELECTRICALOTHER

Product Details

Model Numbers
PROTEUS 235
05404013801138
SBF103 (JP)
SBF124 (EU)
SBF133 (US)
+1 more
Affected States
ALL
Report Date
March 18, 2026
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more